1. Home
  2. PLSE vs IMCR Comparison

PLSE vs IMCR Comparison

Compare PLSE & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pulse Biosciences Inc (DE)

PLSE

Pulse Biosciences Inc (DE)

HOLD

Current Price

$19.11

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

HOLD

Current Price

$30.85

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLSE
IMCR
Founded
2014
2008
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
2015
2016

Fundamental Metrics

Financial Performance
Metric
PLSE
IMCR
Price
$19.11
$30.85
Analyst Decision
Buy
Buy
Analyst Count
1
10
Target Price
$22.00
$66.33
AVG Volume (30 Days)
224.7K
395.4K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
30.39
EPS
N/A
0.25
Revenue
N/A
$249,428,000.00
Revenue This Year
$840.00
$14.57
Revenue Next Year
$287.54
$8.21
P/E Ratio
N/A
N/A
Revenue Growth
N/A
43.05
52 Week Low
$12.56
$27.47
52 Week High
$26.30
$40.71

Technical Indicators

Market Signals
Indicator
PLSE
IMCR
Relative Strength Index (RSI) 41.63 56.34
Support Level $17.32 $28.90
Resistance Level $20.40 $32.24
Average True Range (ATR) 1.43 1.33
MACD -0.44 0.05
Stochastic Oscillator 13.73 73.68

Price Performance

Historical Comparison
PLSE
IMCR

About PLSE Pulse Biosciences Inc (DE)

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Share on Social Networks: